“All the mice we have treated showed a spectacular improvement in their motor skills. The results exceeded our expectations and suggests that after a more in -depth study, this Coultd therapeutic approach slows down the progress of parkinson in humans, “explains Double.

But experts warn that Parkinson is a complex condition that will likely require several combined interventions. A single treatment can have a limited effect, but his life can be improved by interacting with other therapeutic devices.

In this context, the conclusions of the double team could be complex by Research From the University of Stanford, focused on the restoration of Bethaeen communication neurons in a Parkinson subtype linked to changes in the gene responsible for the production of an enzyme called LRRK2.

In these cases, the mutation causes hyperactivity of the enzyme, modifying the structure of cerebral cells and disturbing Bethaeen signaling Dopaminergic neurons And those of the striatum, a region of the deep brain linked to movement, motivation and decision -making.

It is estimated that around 25% of Parkinson cases are of genetic origin, and the LRK2 mutation is one of the frequentations of Mons. The team led by Stanford’s neuroscientist, Suzanne Pfeffer, proposed that the inhibition of the excessive activity of this Coult enzyme could be symmetly, invasive if it was detected at early stages. The objective was to regenerate primary eyelashes, antenna -type structures that allow Bethaeen cells to communicate.

The hypothesis was tested on genetically modified mice to present LRRK2 hyperativity and early syptomes of the disorder. For two weeks, these animals were administered with a compound called MLI-2, which binds to the enzyme and the veteran its activity.

In this first test, no relevant change was observed, which the researchers attacked that the neurond and the glie examined – type of anaper cell in the nervous system, which support neurons – are mature alluial and were not in the cellular division phase.

However, a review of the scientific literature revealed that, even if they are mature, certain neurons can regenerate their primary eyelashes depending on their sleep -wooful cycles. “The results that other non -proliferative cells can develop eyelashes made us think that inhitor always had therapeutic potential,” said Pfeffer.

The team then decides to extend the treatment at three months. After this period, they found that the percentage of neurons and glial cells in the striatum with primary eyelashes was comparable to that of healthy mice without genetic mutation.

This restoration of cellular structures made it possible to reactivate the dopaminergic neurons of communication and the Struiatum. As a resauture, the neurotransmitters affected by the LRRK2 protein induced the production of neuroprotective factors at levels similar to those of a healthy brain, something that had been reduced as resolution of LRRK2 hyperativity. In addition, the density markers of the dopaminergic nerve endings have been doubled, suggesting a possible recovery of predictable neurons.

“These results suggest that it is not only possible for stability of the disease, but also to improve the condition of patients. This therapeutic approach has great potential to restore the activity of neurons in the circuits affected by Parkinson. There are currently several current clinical trials with LRK2 inhitors, and Weope that these results can be translated to humans”, explains Pfeper.

The authors emphasize that, to maximize the effectiveness of this treatment, it is essential to identify Early symptomswhich can look up to 15 years before the characteristic tremors. Hope is that people with LRRK2 mutation will be able to start treatment early. The next step would be to assess where the other variants of Parkinson, not associated with this genetic mutation, could also benefit from this strategy.

It is estimated that the number of cases of sewing in the world of Parkinson exceeds 25 million by 2050, which would respond to 112% incarration on 2021 figures, according to projects Published In the British Medical Journal. Although these estimates are not final, the scientific community warns that they reflect an increasing challenge for public health systems. For this reason, the development of therapies capable of mitigating, staber and even reversing the progression of the disease is a global priority.

This story initially looked at Cable EN ESPAñol and was translated from Spanish.